SecBot SecBot
SECBOTREPLAY Home › Report › DNTH

DNTH · Dianthus Therapeutics reported full-year 2025 financial results and…

Dianthus Therapeutics, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 07:09 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 9, 2026 at 07:09 ET

Dianthus Therapeutics reported full-year 2025 financial results and announced a positive GO decision in the Phase 3 CAPTIVATE trial of claseprubart for CIDP, based on achieving 20 confirmed responders in the interim analysis. The company has $514.4 million in cash, providing a runway into 2028, despite a widening net loss driven by increased R&D spending. Top-line data from multiple late-stage trials are expected in 2026–2028.

  • Achieved early GO decision in Phase 3 CAPTIVATE trial for CIDP based on 20 confirmed responders with less than 40 participants completing Part A.
  • Phase 3 trial in gMG expected to initiate mid-2026 with top-line results in 2H'28.
  • Phase 2 MoMeNtum trial in MMN on track for top-line results in 2H'26.
  • Phase 1 data for DNTH212 in healthy volunteers expected in 2H'26.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access